Monitor for any unexpected opposition or shareholder activism at the meeting, though the board's endorsement and recent reclassification suggest a routine vote. The auditor ratification is standard practice.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 24 $3.29entry
- T+1 · 7mo ago −0.91%α −1.08% · $3.26
- T+5 · 7mo ago 0.00%α −0.91% · $3.29
- T+20 · 6mo ago −4.26%α −8.28% · $3.15
- T+60 · 4mo ago −3.95%α −9.03% · $3.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sana Biotechnology's board is seeking shareholder approval to elect three Class II directors and ratify the appointment of Ernst & Young as auditors. This follows a recent board reclassification to balance director classes, indicating ongoing governance adjustments.
Key Financial Metrics
Key Facts
- Proxy statement seeks approval for three Class II director nominees: Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D.
- Proposal to ratify Ernst & Young as independent auditors for 2026.
- Follows a recent board reclassification of Steven D. Harr from Class I to Class III to balance board classes.
- No other business is expected at the annual meeting.
Financial Impact
No direct financial impact disclosed; governance matters.
Risk Factors
- Potential for shareholder dissent not disclosed in the filing.
- Ernst & Young's auditor independence could be questioned if significant non-audit fees are present.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-174886 |
| Document: 0001193125-26-174886-index-headers.html | 0001193125-26-174886 |
| Document: 0001193125-26-174886-index.html | 0001193125-26-174886 |
| Document: 0001193125-26-174886.txt | 0001193125-26-174886 |
Track record
12 reports on SANA
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +13.50% at T+20 after the May 11, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.37 Now $1.88 −20.68% settles Dec 7
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
- May 11, 202627w ago 8-K Neutral 4/10 No price data
- May 11, 202627w ago Press Release Bearish 6/10 Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 4/10 Viewing Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 24, 202629w ago 8-K Neutral 2/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
- Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers